Comparing a new drug to standard chemo for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called FH-006 against standard chemotherapy for people with advanced esophageal cancer that has stopped responding to previous treatment. The goal is to see if FH-006 can help control the cancer better or with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal squamous cell carcinoma that is locally advanced, recurrent, or has spread to other parts of the body.
- You have already been treated with a PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy, and that treatment has stopped working.
- You have at least one tumor that can be measured on a scan.
- You are in generally good health, able to care for yourself, and have adequate organ function.
- You have not had other cancer treatments within the last 4 weeks, and any side effects from prior treatments have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug called SYS6010 to standard chemotherapy for people with a type of esophageal cancer that has progressed after initial treatment. It aims to see if SYS6010 is more effective and safe, potentially offering a new option for those who need it.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
This study tests whether choosing a treatment based on specific biomarkers (biological clues) works better than the standard approach for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) that has not been treated yet. It aims to improve outcomes by tailoring therapy to each person's cancer.
This trial tests a new drug called KC1036 combined with standard immunotherapy and chemotherapy for people with advanced esophageal cancer that has not been treated before. The goal is to see if this combination can help shrink tumors and improve outcomes.
Hear when a new Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.